Kenneth J. Kelley

Kenneth J. Kelley discloses dealings in Halozyme Therapeutics, Inc. to SEC (Form 4). The record holds 19 filings, for trades running from 4 May 2016 to 14 April 2021.

The open-market side counts 3 purchases for €683k alongside 11 sales for €3.7M. Netting one side against the other leaves €3.0M of net selling. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 5 share grants. Since January 2021: no purchases and 7 sales on the market.

In size, the median ticket on the buying side is €228k. The 3 purchases reviewed show no overlap with other insiders buying the same stock within a month. Looking at 3 purchases old enough to measure, the stock rose over the following 90 days in 100% of cases; the median change was +51.2%. They describe history only and say nothing certain about the share price ahead.

The record was last updated on 14 April 2021 with an open-market sale (€188k) in Halozyme Therapeutics, Inc. The most recent open-market purchase was published on 19 March 2020, 2,409 days ago. The median gap between trade and publication is zero days: most filings appear on the same day. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.